{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:58:19Z","timestamp":1792807099770,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T00:00:00Z","timestamp":1522368000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T00:00:00Z","timestamp":1522368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"U.K. Dermatology Clinical Trials Network (U.K. DCTN)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1111\/bjd.16235","type":"journal-article","created":{"date-parts":[[2017,12,9]],"date-time":"2017-12-09T18:43:04Z","timestamp":1512844984000},"page":"1028-1034","source":"Crossref","is-referenced-by-count":21,"title":["Which outcomes are reported in cellulitis trials? Results of a review of outcomes included in cellulitis trials and a patient priority setting survey"],"prefix":"10.1093","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3355-6369","authenticated-orcid":false,"given":"E.","family":"Smith","sequence":"first","affiliation":[{"name":"Centre of Evidence Based Dermatology; The University of Nottingham; Nottingham U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Primary Care; The University of Nottingham; Nottingham U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-7465","authenticated-orcid":false,"given":"K.S.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology; The University of Nottingham; Nottingham U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,3,30]]},"reference":[{"key":"10.1111\/bjd.16235-BIB0001|bjd16235-cit-0001","doi-asserted-by":"crossref","first-page":"ofv181","DOI":"10.1093\/ofid\/ofv181","article-title":"Etiology of cellulitis and clinical prediction of streptococcal disease: a prospective study","volume":"3","author":"Bruun","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1111\/bjd.16235-BIB0002|bjd16235-cit-0002","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s11908-014-0422-0","article-title":"Recurrent cellulitis: risk factors, etiology, pathogenesis and treatment","volume":"16","author":"Chlebicki","year":"2014","journal-title":"Curr Infect Dis Rep"},{"key":"10.1111\/bjd.16235-BIB0003|bjd16235-cit-0003","unstructured":"National Health Service Hospital episode statistics, admitted patient care, England 2014-15 https:\/\/digital.nhs.uk\/catalogue\/PUB19124"},{"key":"10.1111\/bjd.16235-BIB0004|bjd16235-cit-0004","doi-asserted-by":"crossref","DOI":"10.12968\/bjon.2007.16.Sup1.27089","article-title":"Cellulitis and treatment: a qualitative study of experiences","volume":"16","author":"Carter","year":"2007","journal-title":"Br J Nurs"},{"key":"10.1111\/bjd.16235-BIB0005|bjd16235-cit-0005","first-page":"CD009758","article-title":"Interventions for the prevention of recurrent erysipelas and cellulitis","volume":"6","author":"Dalal","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/bjd.16235-BIB0006|bjd16235-cit-0006","first-page":"CD004299","article-title":"Interventions for cellulitis and erysipelas","author":"Kilburn","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/bjd.16235-BIB0007|bjd16235-cit-0007","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cct.2016.08.010","article-title":"Clinician-reported lesion measurements in skin infection trials: definitions, reliability, and association with patient-reported pain","volume":"50","author":"Powers","year":"2016","journal-title":"Contemp Clin Trials"},{"key":"10.1111\/bjd.16235-BIB0008|bjd16235-cit-0008","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s13063-015-0913-9","article-title":"COS-STAR: a reporting guideline for studies developing core outcome sets (protocol)","volume":"16","author":"Kirkham","year":"2015","journal-title":"Trials"},{"key":"10.1111\/bjd.16235-BIB0009|bjd16235-cit-0009","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1745-6215-13-132","article-title":"Developing core outcome sets for clinical trials: issues to consider","volume":"13","author":"Williamson","year":"2012","journal-title":"Trials"},{"key":"10.1111\/bjd.16235-BIB0010|bjd16235-cit-0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/jid.2014.320","article-title":"The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology","volume":"135","author":"Schmitt","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.16235-BIB0011|bjd16235-cit-0011","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","article-title":"The COMET Handbook: version 1.0","volume":"18","author":"Williamson","year":"2017","journal-title":"Trials"},{"key":"10.1111\/bjd.16235-BIB0012|bjd16235-cit-0012","unstructured":"U.S. Department of Health and Human Services Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. October 2013 https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm071185.pdf"},{"key":"10.1111\/bjd.16235-BIB0013|bjd16235-cit-0013","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/cid\/civ927","article-title":"Developing outcomes assessments as endpoints for registrational clinical trials of antibacterial drugs: 2015 update from the Biomarkers Consortium of the Foundation for the National Institutes of Health","volume":"62","author":"Talbot","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1111\/bjd.16235-BIB0014|bjd16235-cit-0014","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjd.15634","article-title":"Identifying priority areas for research into the diagnosis, treatment and prevention of cellulitis (erysipelas): results of a James Lind Alliance Priority Setting Partnership","volume":"177","author":"Thomas","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16235-BIB0015|bjd16235-cit-0015","unstructured":"Centre of Evidence Based Dermatology Protocol Registration. Which outcomes should we measure in cellulitis trials? Results of a systematic review of outcomes used in cellulitis trials and a patient priority setting survey http:\/\/www.nottingham.ac.uk\/research\/groups\/cebd\/documents\/methodological-resources\/protocol-outcomes-cellulitis.pdf"},{"key":"10.1111\/bjd.16235-BIB0016|bjd16235-cit-0016","first-page":"191","volume-title":"Human Motives and Cultural Models","author":"Strauss","year":"1992"},{"key":"10.1111\/bjd.16235-BIB0017|bjd16235-cit-0017","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0399-077X(05)80579-7","article-title":"Benzathine penicillin prophylaxis in recurrent erysipelas","volume":"24","author":"Chakroun","year":"1994","journal-title":"Med Mal Infect"},{"key":"10.1111\/bjd.16235-BIB0018|bjd16235-cit-0018","first-page":"2227","article-title":"Sodium selenite as prophylaxis against erysipelas in secondary lymphoedema","volume":"18","author":"Kasseroller","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1111\/bjd.16235-BIB0019|bjd16235-cit-0019","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0163-4453(91)90898-3","article-title":"Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections","volume":"22","author":"Kremer","year":"1991","journal-title":"J Infect"},{"key":"10.1111\/bjd.16235-BIB0020|bjd16235-cit-0020","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/BF01728920","article-title":"Antibiotic prophylaxis in recurrent erysipelas","volume":"21","author":"Sjoblom","year":"1993","journal-title":"Infection"},{"key":"10.1111\/bjd.16235-BIB0021|bjd16235-cit-0021","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2133.2011.10586.x","article-title":"Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the U.K. Dermatology Clinical Trials Network's PATCH II trial","volume":"166","author":"Thomas","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16235-BIB0022|bjd16235-cit-0022","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1206300","article-title":"Penicillin to prevent recurrent leg cellulitis","volume":"368","author":"Thomas","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.16235-BIB0023|bjd16235-cit-0023","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/cid\/ciw463","article-title":"Early response in cellulitis: a prospective study of dynamics and predictors","volume":"63","author":"Bruun","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1111\/bjd.16235-BIB0024|bjd16235-cit-0024","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s10096-017-3001-0","article-title":"Clinical condition and comorbidity as determinants for blood culture positivity in patients with skin and soft-tissue infections","volume":"36","author":"Daalen","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/bjd.16235-BIB0025|bjd16235-cit-0025","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jaci.2007.08.011","article-title":"What are the best outcome measurements for atopic eczema? A systematic review","volume":"120","author":"Schmitt","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.16235-BIB0026|bjd16235-cit-0026","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1365-2133.2012.11056.x","article-title":"Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials","volume":"167","author":"Eleftheriadou","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16235-BIB0027|bjd16235-cit-0027","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2133.2008.08819.x","article-title":"Outcome measures in acne vulgaris: systematic review","volume":"160","author":"Barratt","year":"2009","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.16235","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.16235\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:38:27Z","timestamp":1676381907000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/178\/5\/1028\/6752997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,30]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.16235","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3,30]]}}}